Novartis AG & Anor v Teva UK Ltd & Ors [2022] EWCA Civ 775 (25 May 2022)

Novartis AG & Anor v Teva UK Ltd & Ors [2022] EWCA Civ 775 (25 May 2022)

The judge was entitled to find that damages would be an adequate remedy for Novartis, given the market structure, NHS tendering, and short period to trial; there was no real prospect of success in challenging the refusal of interim injunction or the judge's factual findings.

Citation
[2022] EWCA Civ 775
Parties
Appellant / Claimant: Novartis AG; Appellant / Claimant: Novartis Pharmaceuticals UK Limited; Respondent / Defendant: Teva UK Limited; Respondent / Defendant: Dr. Reddy's Laboratories (UK) Limited; Respondent / Defendant: Glenmark Pharmaceuticals Europe Limited; Respondent / Defendant: Tillomed Laboratories Limited; Respondent / Defendant: Zenvita Pharma UK Limited; Respondent / Defendant: Aristo Pharma GmbH; Respondent / Defendant: Viatris UK Healthcare Limited
Jurisdiction
England and Wales
Judgment Date
25 May 2022
Procedural Posture
Appeal (interim Injunction Refusal) / Permission to Appeal Application
Outcome
Permission to appeal refused
Legal Topics
Interim Injunctions, Patent Validity, Pharmaceutical Patents, Adequacy of Damages, Balance of Convenience
Intellectual Property Patents Interim Injunctions Patent Validity Pharmaceutical Patents Adequacy of Damages Balance of Convenience

Case Brief

Summary, issues, holding and outcome

More case intelligence is available

Unlock the full research layer for this judgment.

Full judgment text Downloadable case file Legal principles 3 Authorities cited 3 Party arguments 2
Sign in to unlock

Parties

Novartis AG

Appellant / Claimant

Novartis Pharmaceuticals UK Limited

Appellant / Claimant

Teva UK Limited

Respondent / Defendant

Dr. Reddy's Laboratories (UK) Limited

Respondent / Defendant

Glenmark Pharmaceuticals Europe Limited

Respondent / Defendant

Tillomed Laboratories Limited

Respondent / Defendant

Zenvita Pharma UK Limited

Respondent / Defendant

Aristo Pharma GmbH

Respondent / Defendant

Viatris UK Healthcare Limited

Respondent / Defendant

Procedural Posture

Appeal (interim Injunction Refusal) / Permission to Appeal Application

Legal Issues

  1. 1 Whether interim injunction should be granted pending trial in a pharmaceutical patent dispute
  2. 2 Whether damages are an adequate remedy for the patentee
  3. 3 Whether the balance of convenience favours granting an injunction

Ratio Decidendi

The judge was entitled to find that damages would be an adequate remedy for Novartis, given the market structure, NHS tendering, and short period to trial; there was no real prospect of success in challenging the refusal of interim injunction or the judge's factual findings.

Court Disposition

Permission to appeal refused

Orders

  • No order as to costs